National guidelines for the management of hepatitis C virus infection in drug users in Slovenia;Nacionalne usmeritve obvladovanja okužbe z virusom hepatitisa C pri uživalcih drog v Sloveniji

Zdravniski Vestnik

Volumn 78, Issue 10, 2009, Pages 529-539

  Matičič, Mojca ^a   Kastelic, Andrej ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b Psihiatri na Klinika Ljubljana   (Slovenia)

Author keywords

Drug users; Hepatitis C; National guidelines; Slovenia

Indexed keywords

EID: 79951867601     PISSN: 13180347     EISSN: 15810224     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B (Pubitemid 19117877)
2. Anon. World Health Organisation: Weekly epidemiological record, 1999; 74: 421-508.
3. Anon. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: S84-7.
4. Matičič M, Poljak M, Lunder T, Rener-Sitar K, Stojanovič L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre-and post-interferon based treatment prevalences vary in a cohort of patients from low hepatitis C virus endemic area. JEADV 2008; 22: 779-788. (Pubitemid 351837110)
5. Seme K, Poljak M, Brinovec V, Lešničar G. Uporabnost seroloških testov tretje generacije v posredni diagnostiki okužbe z virusom hepatitisa C. Zdrav Vestn 1995; 64 Suppl 3: 9-12.
6. Poljak M, Seme K, Koren S. Evaluation of automated COBAS AMPLICOR hepatitis C virus PCR system. J Clin Microbiol 1997; 35: 2983-4. (Pubitemid 27452450)
7. Seme K, Poljak M, Lesničar G, Brinovec V, Štepec S, Koren S. Distribution of hepatitis C virus genotypes in Slovenia. Scand J Infect Dis 1997; 29: 29-31.
8. Seme K, Poljak M, Žužek-Rešek S, Avšič-Žu-panc T. High prevalence of hepatitis C virus infection in hemodialysis patients from one dialysis unit in Slovenia. Nephron 1995; 71: 99-100.
9. Matičič M, Brinovec V, Lešničar G, Vidmar L, Meglič-Volkar J. Hepatitis C v Sloveniji. ISIS 1999; 8: 49-51.
10. Planinc N, Matičič M. Računalniška podpora pri klinični obravnavi bolnikov s kroničnim hepatitisom C. In: Kongres medicinske informatike 2008. 2008 Oct 9-10; Zreče, Slovenija. Ljubljana: Slovensko društvo za medicinsko informatiko; 2008. p. 80-6.
11. th Memorial Meeting of Professor Janez Plečnik with International Participation. 2004 Dec 2-3; Ljubljana, Slovenija. Ljubljana: Institute of Pathology, Faculty of Medicine, University of Ljubljana, 2004. p. 281-3.
12. th European Congress of Clinical Microbiology and Infectious Diseases. 1995 Mar; Vienna, Austria. Vienna: European Society of Clinical Microbiology and Infectious Diseases, 1995. p. 180.
13. Brinovec V, Lešničar G, Matičič M, Meglič-Volkar J, Poljak M, Seme K, et al. Efficacy of chronic hepatitis C therapy with interferon alpha (IFN a) in Slovenia. Hepato-Gastroente-rol 2002; 49: 1320-5.
14. Brinovec V, Lešničar G, Meglič-Volkar J, Matičič M, Baklan Z, Poljak M, et al. Treatment of chronic hepatitis C: our experience. Hepato-Gastroenterol 2004; 51: 494-9. (Pubitemid 38445304)
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65. (Pubitemid 32913521)
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
17. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomised study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
18. Harder J, Walter E, Riecken B, Ihling C, Bauter TM. Hepatitis C virus infection in intravenous drug users. Clin Microbiol Infect 2004; 10: 768-70. (Pubitemid 39232698)
19. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L. Monitoring of hepatitis C virus infection among intravenous drug users in European union: a review of the literature. Epidemiol Infect 2002; 129: 577-85. (Pubitemid 36157682)
20. Gordon SC, Elloway RS, Long LC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993; 18: 1338-43. (Pubitemid 23348419)
21. Mathei C, Buntix F, van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systemic review. J Virol 2002; 9: 157-73. (Pubitemid 36005513)
22. Nolimal D. Tehnike souporabljanja pribora za vbrizgavanje, družbeni okvir in preprečevanje okužb s krvjo pri uporabnikih drog. Zdrav Var 2000; 39: 56-2.
23. Klavs I. Infekcijske bolezni zaradi prepovedanih drog v Sloveniji. In: Lovrečič M, ed. Poročilo s področja prepovedanih drog v Republiki Sloveniji. Ljubljana: Inštitut za varovanje zdravja Republike Slovenije; 2007. p.118.
24. Baklan Z, Poljak M, Fras-Stefan T, Pišec A, Krek J. Prevalence of HIV, hepatitis B and C among intravenous drug users on methadone maintenance treatment in Slovenia. Clin Microbiol Infect 2006: 12 Suppl 4: 2190.
25. st World Conference on Medication Assisted Treatment of Opiate Addiction. 2007 Jul 2-4. Ljubljana, Slovenia. EUROPAD, AATOD, SEEA net; 2007. p. 29-30.
26. Anon. National Institutes of Health. Consensus Development Conference. Management of Hepatitis C. Hepatology 2002; 36: S3-S20.
27. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenetic and clinical implications. Clin Liver Dis 2003; 7: 45-66.
28. Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol 2001; 44: 159-82.
29. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 2001; 8: 200-6. (Pubitemid 32672971)
30. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32. (Pubitemid 27129209)
31. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of hepatitis C virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39: 2-17. (Pubitemid 46039435)
32. Harris KR, Dighe AS. Laboratory testing for viral hepatitis. Am J Clin Pathol 2002; 118: S18-S25.
33. Seme K, Močilnik T, Fujs K, Babič DZ, Todorovič A, Fras-Stefan T, et al. Twenty-four mini-pool HCV RNA screening outside a blood transfusion setting: results of a 2-year prospective study. J Virol Methods 2007; 140: 218-21. (Pubitemid 46185599)
34. 34-Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 week treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103. (Pubitemid 41772522)
35. 35- McHutchhinson JG. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
36. Chevaliez S, Pawlotsky JM. How to use virological tools for optimal management of chronic hepatitis C. Liver International 2009; 29 Suppl 1: 9-14.
37. Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver International 2009; 29 Suppl 1: 15-18.
38. Fried MW, Hadzyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. J Hepatol 2008; 48 Suppl 2: 5.
39. Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the »accordion« regimen? J Hepatol 2007; 352: 2609-17.
40. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa 2-b and ribavirin for 12 vs 24 weeks in HCV genotypes 2 or 3. N Engl J Med 2005; 352: 2609-17. (Pubitemid 41007847)
41. Heathcote J. Tretreatment of chronic hepatitis C: who and how? Liver International 2009; 29 Suppl 1: 49-56.
42. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004; 78: 955-63. (Pubitemid 39391854)
43. th Memorial Meeting of Professor Janez Plečnik with International Participation. 2004 Dec 2-3; Ljubljana, Slovenija. Ljubljana: Institute of Pathology, Faculty of Medicine, University of Ljubljana, 2004. p. 284-9.
44. Jaeckel E, Cornberg M, Wedemeyer H, Santantoio T, Mayer J, Zenkel M, et al. German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.
45. Wejstal R, Aleaus A, Fischler Breichard O, Uhnoo I, Weilamd O. Chronic hepatitis C: Updated Swedish Consensus. Scand J Infect Dis 2003; 35: 445-51. (Pubitemid 37142430)
46. Fried MW. Side-effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-S44. (Pubitemid 35253486)
47. Kastelic A, Kostnapfel-Rihtar T. Ten years of organised drug addiction treatment in the Republic of Slovenia. Zdrav Var 2005; 44: 111-2.
48. WHO/UNODC/UNAIDS. Substitution maintainance therapy in the management of opioid dependence and HIV/aids prevention position paper. World Health Organisation 2004. Dosegljivo na: www.who.int
49. Eramova I, Matic S, Munz M. Prevention of hepatitis A, B and C and other hepatotoxic factors in people living with HIV/aids. Clinical protocol for the WHO European region. World Health Organisation 2006. Dosegljivo na: www.euro.who.int
50. th Memorial Meeting of Professor Janez Plečnik with International Participation. 2004 Dec 2-3; Ljubljana, Slovenija. Ljubljana: Institute of Pathology, Faculty of Medicine, University of Ljubljana, 2004. p. 363-77.
51. Pravilnik o prijavi nalezljivih bolezni in posebnih ukrepih za njihovo preprečevanje in obvladovanje. Ur l RS 16/99.
52. CDC. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health care and public saftey workers. MMWR 1989; 38 Suppl 6: 1-37.
53. Miller R. Background to clinical counselling in HIV disease. In: Miller R, Bor R, eds. AIDS - a guide to clinical counselling. Philadelphia: Science Press; 1991. p. 11-8.
54. Matičič M. Celostna obravnava bolnika s hepatitisom C. In: Kopčavar-Guček N, Petek D, eds. Kakovostna obravnava bolnika v družinski medicini. 34. srečanje delovnih skupin; 2008 May 23-24. Ljubljana, Slovenija. Ljubljana: Združenje zdravnikov družinske medicine; 2008. p. 55-60.
55. th Memorial Meeting of Professor Janez Plečnik with International Participation. 2004 Dec 2-3; Ljubljana, Slovenija. Ljubljana: Institute of Pathology, Faculty of Medicine, University of Ljubljana, 2004. p. 158-73.
56. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
57. Ferlan-Marolt V. Standardizacija patohistološke diagnoze v hepatologiji. Zdrav Vestn 1997; 66: 31-3.
58. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C. AASLD practical guideline. Hepatology 2004; 39: 1147-71.
59. Caurnot M, Gilbert A, Castel F. Management of hepatitis C in active drug users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004; 28: 533-9. (Pubitemid 38917484)
60. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207-11.
61. Shaefer M, Schmid F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-51. (Pubitemid 36152544)
62. Kraus MR, Shaffer A, Shottker K, Keicher C, Weissbrich B, Hofbauer I, et al. Therapy of interferon induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo controlled study. Gut 2008; 57: 531-6. (Pubitemid 351442539)
63. Taylor D, Paton C, Kerwin R. The Maudsley 2005-2006 Perscribing Guidelines. London: Taylor & Francis; 2006.
64. Zanetti AR, Tanzi E, Newel ML. Mother-to-in-fant transmission of hepatitis C virus. J Hepatol 1999; 31 Suppl 1: 96-100.